In a report with 125 imatinib-resistant CML patients, 28 (22.4%) showed a BCR::ABL1 kinase domain mutation, from which 7.2% had T315I and 3.2% had E255K [50]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.